Lipikind-Plus Capsule is a combination pharmaceutical formulation containing Aspirin (75 mg), Atorvastatin (10 mg), and Clopidogrel (75 mg), indicated for the prevention and management of cardiovascular diseases. Aspirin acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase-1 (COX-1), thereby reducing thromboxane A2 synthesis and platelet aggregation, which helps prevent arterial thrombosis. Atorvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels, contributing to the reduction of atherosclerotic plaque progression. Clopidogrel is a P2Y12 receptor antagonist that inhibits ADP-mediated platelet activation and aggregation, providing an additive antiplatelet effect alongside aspirin. This combination is primarily utilized in patients at high risk for acute coronary syndromes, myocardial infarction, stroke, and other thrombotic events, especially those with established atherosclerotic cardiovascular disease or undergoing percutaneous coronary interventions. The synergistic action of these agents offers comprehensive cardiovascular protection through lipid lowering and dual antiplatelet therapy. Lipikind-Plus should be administered under medical supervision, considering contraindications such as active bleeding, hypersensitivity, or hepatic impairment. Regular monitoring of liver function, lipid profile, and bleeding parameters is recommended during therapy to optimize safety and efficacy.